OASIS Phase IIIb study with Jetrea (ocriplasmin) in patients with symptomatic vitreomacular adhesion published in Opthalmology - ThromboGenics
ThromboGenics has announced that the results from its 2 Year OASIS Phase IIIb study with Jetrea (ocriplasmin) in patients with symptomatic vitreomacular adhesion (sVMA) have been published in Ophthalmology. Ophthalmology reviewed the OASIS study which was a Phase IIIb randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for Jetrea in patients being treated for symptomatic vitreomacular adhesion. The study included 24 months follow up data, the longest period patients have been studied post treatment with this novel medicine. In its overall conclusion, the study confirms 'the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase III trials with no additional safety signals identified'.
The OASIS study results, including the sub-study read out, will be the subject of various presentations delivered at upcoming US and global retina specialists educational meetings, such as the 34th Annual Scientific Meeting of the American Society of Retina Specialists, and the Annual Meeting of the American Academy of Ophthalmology.
See: "Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial" Pravin U. Dugel et al. Opthalmology, Published Online: August 04, 2016 DOI: http://dx.doi.org/10.1016/j.ophtha.2016.06.043
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)